维普中文期刊产品整合服务
199篇 您的检索式:作者名="PETER D N"
    题名 作者 年代 出处 被引量
1Retrograde-viewing device improves adenoma detection rate in colonoscopies for surveillance and diagnostic workup显示文摘AIM:To determine which patients might benefit most from retrograde viewing during colonoscopy through subset analysis of randomized,controlled trial data.METHODS:The Third Eye Retroscope Randomized Clinical Evaluation(TERRACE) was a randomized,controlled,multicenter trial designed to evaluate the efficacy of a retrograde-viewing auxiliary imaging device that is used during colonoscopy to provide a second video image which allows viewing of areas on the proximal aspect of haustral folds and flexures that are difficult to see with the colonoscope's forward view.We performed a post-hoc analysis of the TERRACE data to determine whether certain subsets of the patient population would gain more benefit than others from use of the device.Subjects were patients scheduled for colonoscopy for screening,surveillance or diagnostic workup,and each underwent same-day tandem examinations with standard colonoscopy(SC) and Third Eye colonoscopy(TEC),randomized to SC followed by TEC or vice versa.RESULTS:Indication for colonoscopy was screening in 176/345 subjects(51.0%),surveillance after previous polypectomy in 87(25.2%) and diagnostic workup in 82(23.8%).In 4 subjects no indication was specified.Previously reported overall results had shown a net additional adenoma detection rate(ADR) with TEC of 23.2% compared to SC.Relative risk(RR) of missing adenomas with SC vs TEC as the initial procedure was 1.92(P = 0.029).Post-hoc subset analysis shows additional ADRs for TEC compared to SC were 4.4% for screening,35.7% for surveillance,55.4% for diagnostic and 40.7% for surveillance and diagnostic combined.The RR of missing adenomas with SC vs TEC was 1.11(P = 0.815) for screening,3.15(P = 0.014) for surveillance,8.64(P = 0.039) for diagnostic and 3.34(P = 0.003) for surveillance and diagnostic combined.Although a multivariate Poisson regression suggested gender as a possibly significant factor,subset analysis showed that the difference between genders was not statistically significant.Age,bowel prep quality and withdrawal time did not significantly affect the RR of missing adenomas with SC vs TEC.Mean sizes of adenomas detected with TEC and SC were similar at 0.59 cm and 0.56 cm,respectively(P = NS).CONCLUSION:TEC allows detection of significantly more adenomas compared to SC in patients undergoing surveillance or diagnostic workup,but not in screening patients(ClinicalTrials.gov Identifier:NCT01044732).Peter D Siersema Amit Rastogi Anke M Leufkens Paul A Akerman Kassem Azzouzi Richard I Rothstein Frank P Vleggaar Alessandro Repici Giacomo Rando Patrick I Okolo Olivier Dewit Ana Ignjatovic Elizabeth Odstrcil James East Pierre H Deprez Brian P Saunders Anthony N Kalloo Bradley Creel Vikas Singh Anne Marie Lennon Daniel C DeMarco 2012World Journal of Gastroenterology2012,18,26:6
2Randomized trial in malignant biliary obstruction:Plastic vs partially covered metal stents显示文摘AIM:To compare efficacy and complications of par-tially covered self-expandable metal stent(pcSEMS)to plastic stent(PS)in patients treated for malignant,infrahilar biliary obstruction.METHODS:Multicenter prospective randomized clinical trial with treatment allocation to a pcWallstent(SEMS)or a 10 French PS.Palliative patients aged≥18,for infrahilar malignant biliary obstruction and a Karnofsky performance scale index>60%from 6 participating North American university centers.Primary endpoint was time to stent failure,with secondary outcomes of death,adverse events,Karnofsky performance score and short-form-36 scale administered on a three-monthly basis for up to 2 years.Survival analyses were performed for stent failure and death,with Cox proportional hazards regression models to determine significant predictive characteristics.RESULTS:Eighty-five patients were accrued over 37mo,42 were randomized to the SEMS group and 83patients were available for analyses.Time to stent failure was 385.3±52.5 d in the SEMS and 153.3±19.8 d in the PS group,P=0.006.Time to death did not differ between groups(192.3±23.4 d for SEMS vs211.5±28.0 d for PS,P=0.70).The only significant predictor was treatment allocation,relating to the time to stent failure(P=0.01).Amongst other measured outcomes,only cholangitis differed,being more common in the PS group(4.9%vs 24.5%,P=0.029).The small number of patients in follow-up limits longitudinal assessments of performance and quality of life.From an initially planned 120 patients,only 85 patients were recruited.CONCLUSION:Partially covered SEMS result in a longer duration till stent failure without increased complication rates,yet without accompanying measurable benefits in survival,performance,or quality of life.Peter L Moses Khalid M AlNaamani Alan N Barkun Stuart R Gordon Roger D Mitty M Stanley Branch Thomas E Kowalski Myriam Martel Viviane Adam 2013World Journal of Gastroenterology2013,19,46:6
3重组脊髓灰质炎病毒用于治疗复发胶质母细胞瘤(英文)显示文摘Background The prognosis of patients with recurrent World Health Organization(WHO)grade IV malignant glioma is dismal,and there is currently no effective therapy.We conducted a dose-finding and toxicity study in this population of patients,evaluating convection-enhanced,intratumoral delivery of the recombinant nonpathogenic polio-rhinovirus chimera(PVSRIPO).PVSRIPO recognizes the poliovirus receptor CD155,which is widely expressed in neoplastic cells of solid tumors and in major components of the tumor microenvironment.Methods We enrolled consecutive adult patients who had recurrent supratentorial WHO grade IV malignant glioma,confirmed on histopathological testing,with measurable disease(contrast-enhancing tumor of≥1 cm and≤5.5 cm in the greatest dimension).The study evaluated seven doses,ranging between 107 and 1010 50%tissue-culture infectious doses(TCID50),first in a dose-escalation phase and then in a dose-expansion phase.Results From May 2012 through May 2017,a total of 61 patients were enrolled and received a dose of PVSRIPO.Dose level-1(5.0×107TCID50)was identified as the phase 2 dose.One dose-limiting toxic effect was observed;a patient in whom dose level 5(1010TCID50)was administered had a grade 4 intracranial hemorrhage immediately after the catheter was removed.To mitigate locoregional inflammation of the infused tumor with prolonged glucocorticoid use,dose level 5 was deescalated to reach the phase 2 dose.In the dose-expansion phase,19%of the patients had a PVSRIPO-related adverse event of grade 3 or higher.Overall survival among the patients who received PVSRIPO reached a plateau of 21%(95%confidence interval,11 to 33)at 24 months that was sustained at 36 months.Conclusions Intratumoral infusion of PVSRIPO in patients with recurrent WHO grade IV malignant glioma confirmed the absence of neurovirulent potential.The survival rate among patients who receivedPVSRIPO immunotherapy was higher at 24 and 36 months than the rate among historical controls.Desjardins A Gromeier M Herndon JE 2nd Beaubier N Bolognesi DP Friedman AH Friedman HS McSherry F Muscat AM Nair S Peters KB Randazzo D Sampson JH Vlahovic G Harrison WT McLendon RE Ashley D Bigner DD 2018中华神经外科疾病研究杂志2018,17,4:2
4Palladium - substituted lanthanum cuprates:Application to automotive exhaust purification 显示文摘Guilhaume N Peter S D Primet M 1996Applied Catalysis B: Environmental1996,10,:1
5Development of a laser Raman spectrometer for deep-ocean science显示文摘Peter G Brewer George Malby Jill D Pasteris Sheri N White Edward T Peltzer B Wopenka J Freeman Mark O Brown 2004Deep-Sea Research Part I2004,,5:1
6Heat-shock protein 70-dependent dendritic cell activation by 5-aminolevulinic acid-mediated photodynamic treatment of human glioblas- toma spheroids in vitro 显示文摘Etminan N Peters C Lakbir D 2011Br J Cancer2011,105,7:1
7Effects of microscan operation on staring infrared sensor imagery显示文摘BLOMMEL F P DENNIS Dr Peter N J BRADLEY Dr D 1991SPIE1991,1540,:1
8Field dvices-models and their Realisation显示文摘RENE S PETER N CHRISTIAN D 2002Industrial Technology2002,4,:1
9A comparison of dental and dentoalveolar changes between rapid palatal expansion and nickel-titanium palatal expansion显示文摘Christopher C Peter N Mark D 2001Am J Orthod Dentofacial Orthop2001,19,1:1
10Fas associated death domain protein FADD and caspase8 mediate up regulation of F cos by Fas ligand and tumor necrosis factor related apoptosis inducing ligand(TRAIL) via FLICE inhibitory protein(FLIP)regulated pathway 显示文摘Siegmund D Mauri D Peters N 2007Biol Chem2007,276,32:1
11查看详情显示文摘N(o)r J E Christensen J Liu J Peters M Mooney D J Strieter R M Polverini P J 0,,05:1
12Selenium deficiency increases the pathology of an influenza virus infection显示文摘Melinda A B Heather K N Peter V D 2001FASEB2001,10,:1
13Effect of calcium ions on the irreversible denaturation of a recombinant Bacillus halmapalus α-am- ylase:a calorimetric investigation显示文摘ANDERS D N CLAUS C F PETER W 2003Biochemistry Journal2003,373,:1
14Nucleosides in sow colostnuns and milk at different stages of lactation显示文摘Mateo C D Peters D N Stein H H 2004J Amin Sci2004,82,:1
15Multieenter evaluation of the new Ahbott RealTime assays for quantitative detection of human immunodeficiency virus type 1 and hepatitis C virus RNA显示文摘Sehutten M Peters D Back N 2007J Clin Microhiol2007,45,6:1
16Use of fibrin sealant in the pre-vention of seromas 显示文摘Kulber D A Bacilious N Peters E D 1997Plast Reconstr Surg1997,99,3:1
17Fas-associated Death Domain and caspase-8 mediate up-regulation of c-fos by Fas ligand and Tumor Necrosis Factor-related apoptosis-inducing ligand(TRAIL) via FLICE Inhibitory Protein(FLIP) 显示文摘Siegmund D Mauri D Peter N 2001J Biol Chem2001,276,32:1
18Earnings management and investor protection:an international comparison显示文摘Leuz C Dhananjay N Peter D 2003Journal of Financial Economics2003,69,3:1
19Real-time dynamic optimization of batch systems显示文摘Peters N Guay M DeHaan D 2007Journal of Process Control2007,17,3:1
20Analysis of high frequency microseismicity recorded at an underground hardrock mine显示文摘BUTT S D DEREK B A PETER N C 1997Pure and Applied Geophysics1997,150,34:1
返回顶部 每页显示:
共10页 首页 上一页 第1页 下一页 末页 /10 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费